At Achillion, we are driven to transform the lives of patients and families affected by diseases of the complement system, an integral part of the innate immune system. Scientific and clinical evidence has implicated the complement system, and specifically the complement Alternative Pathway (AP), in numerous devastating diseases and conditions. Our principal focus at Achillion is to advance our clinical-stage portfolio of orally administered factor D inhibitors into late-stage development and potential commercialization for patients with devastating disorders of the AP. Source
No articles found.
We enable cheaper, faster, and better genetic engineering of plants. We offer our ...
We enable cheaper, faster, and better genetic e...
With operations in South San Francisco, CA and Research Triangle Park, NC, Satsuma...
With operations in South San Francisco, CA and ...
Tabula Rasa HealthCare (TRHC) is a leader in providing patient-specific, data-driv...
Tabula Rasa HealthCare (TRHC) is a leader in pr...
Founded 20 years ago, Seattle Genetics was built on a foundation of scientific inn...
Founded 20 years ago, Seattle Genetics was buil...
Join the National Investor Network and get the latest information with your interests in mind.